Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial data-Reference-Cited by-同舟云学术

Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial data

Published:2019-02-28 Issue:4 Volume:32 Page:576-583
ISSN:1755-1471
Container-title:Pigment Cell & Melanoma Research
language:en
Short-container-title:Pigment Cell Melanoma Res

Author:

Hopkins Ashley M.¹^ORCID,Van Dyk Madele¹,Rowland Andrew¹,Sorich Michael J.¹

Affiliation:

1. Flinders Centre for Innovation in Cancer & Department of Clinical Pharmacology, College of Medicine and Public Health Flinders University Adelaide South Australia Australia

Funder

National Breast Cancer Foundation

Cancer Council South Australia

Publisher

Wiley

Subject

Dermatology,General Biochemistry, Genetics and Molecular Biology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/pcmr.12773

Reference23 articles.

1. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

2. The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy